Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Russian Ministry of Defense: 37 Ukrainian drones destroyed in 4 hours over regions of Russia and the Black Sea.
Sheikh Qassem: Our supporters make up more than half of Lebanon's population, and all of these people are united under the banner of protecting Lebanon, its Resistance, its people, and its integrity.
Sheikh Qassem: There will be no phased handing in of our arms. [The Israelis] must first enact the agreement before we start talking about a defensive strategy.
Sheikh Qassem: Be brave in the face of foreign pressures, and we will be by your side in this stance.
Sheikh Qassem: Stripping us of our arms is like stripping us of our very soul, and this will prompt us to show them our might.
Sheikh Qassem: We will not abandon our arms, for they gave us dignity; we will not abandon our arms, for they protect us against our enemy.
Sheikh Qassem: The US efforts we are seeing are aimed at sabotaging Lebanon and constitute a call for sedition.
Sheikh Qassem: If you truly want to establish sovereignty and work for Lebanon’s interests, then stop the aggression.
Sheikh Qassem: The United States, which is meddling in Lebanon, is not trustworthy but rather poses a danger to it.
Sheikh Qassem: The United States is preventing the weapons that protect the homeland.

CAR T Cell Therapy reaches beyond cancer

  • By Al Mayadeen English
  • Source: Agencies
  • 24 Nov 2022 18:32
  • 1 Shares
4 Min Read

A Penn Medicine CAR T pioneer and a doctoral student in Cell and Molecular Biology discuss the development and progress in treating certain B cell leukemia, lymphoma, and other blood cancers.

  • x
  • CAR T Cell Therapy Reaches Beyond Cancer (Photo: Credit: Keith Chambers / Science Photo Library / Getty Images)
    Researchers have reported highly promising early results for CAR T therapy in a small group of patients with the autoimmune disease lupus. (Photo: Credit: Keith Chambers / Science Photo Library / Getty Images)

Chimeric antigen receptor cells (CAR T), or engineered immune cells, have revealed the ability of personalized immunotherapies to fight blood cancers. Now, researchers have reported highly promising early results for CAR T therapy in a small group of patients with the autoimmune disease lupus. Penn Medicine CAR T pioneer Carl June, MD, and Daniel Baker, a doctoral student in Cell and Molecular Biology in the Perelman School of Medicine at the University of Pennsylvania, discuss this progress in a commentary published today in Cell.

"We've always known that in principle, CAR T therapies could have broad applications, and it's very encouraging to see early evidence that this promise is now being realized," said June, who is the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine at Penn Medicine and director of the Center for Cellular Immunotherapies at Penn's Abramson Cancer Center.

Read: Immunotherapy treatment "cures" 2 cancer patients

T cells are among the immune system's most powerful weapons. They can bind to and kill the cells they see as valid targets, including cells infected by viruses. CAR T cells are T cells that have been redirected to effectively kill specifically defined cell types, through genetic engineering.

How are CAR T therapies created?

The cells of each patient are what make CAR T therapies; they are collected from the patient's blood and engineered and multiplied in a lab before they are re-infused into the patient as a "living drug."

The first CAR T therapy, Kymriah, was developed by June and his team at Penn Medicine. It was approved by the Food and Drug Administration in 2017. There are now six FDA-approved CAR T cell therapies in the United States for six different cancers. The therapies have created a revolution in the treatment of certain B cell leukemia, lymphoma, and other blood cancers. Many patients who had little hope have now been put into long-term remission.

Since the beginning of the research, experts believed that T cells could be engineered to fight many conditions other than B cell cancers. These potential new applications are being examined by dozens of research teams around the globe.

The commentary from Baker and June comes in response to the first significant clinical report about the success resulting from these efforts: a paper in Nature Medicine by German researchers on the CAR T therapy used to fight the autoimmune disease lupus (systemic lupus erythematosus).

Lupus, according to researchers, is an obvious choice for CAR T therapy because it, too, is driven by B cells. Thus, experimental CAR T therapies can employ existing anti-B-cell designs. B cells are the immune system's antibody-producing cells, and, in lupus, B cells arise and attack the patient's own organs and tissues.

In the German study, the patients, five young adults, did not benefit from standard lupus treatments. Yet, they all went into remission and were able to stop taking their lupus drugs within three months of a single, relatively small dose of CAR T therapy, which essentially removed their existing B cells.

What was even more noticeable is that all the patients remained in remission during the follow-up period of up to a year, and unlike cancer patients, the lupus patients' B cells came back. They are naturally replenished from blood stem cells in the bone marrow.

June and Baker noted in their commentary that, although the German study's results should be confirmed with bigger studies and longer-term follow-up, they are significantly promising. They suggest that lupus could turn out to be an easier CAR T target than B-cell cancers.

"Disease-driving B cells are much less numerous in lupus," Baker said. "Thus, effective CAR T treatment of this autoimmune disease may require a much lower dose that greatly reduces the problem of immunological side-effects."

  • Cell Therapy
  • Car T
  • Cancer
  • Engineered immune cells

Most Read

Tom Artiom Alexandrovich, executive director of the defense division of the Israeli National Cyber Directorate, undated (Social media)

Israeli-born US prosecutor drops Israeli officer child sex crime

  • Politics
  • 19 Aug 2025
Almost instantly after the Helsinki Accords were signed, organisations sprouted to document purported violations, whose findings were fed to overseas embassies for international amplification. (Al Mayadeen English; Illustrated by Zeinab el-Hajj)

How ‘Human Rights’ became a Western weapon

  • Opinion
  • 23 Aug 2025
Israeli soldiers stand on the top of armoured vehicles parked on an area near the Israeli-Gaza border, as seen from southern Israel, Wednesday, Aug. 20, 2025 (AP)

Palestinian fighters target Israeli soldiers, vehicles in Gaza

  • Politics
  • 21 Aug 2025
Launch of a ballistic missile from Yemen toward the occupied Palestinian territories. (YAF military media)

Yemeni Forces announce firing hypersonic missile at Al-Lydd Airport

  • Politics
  • 22 Aug 2025

Coverage

All
The Ummah's Martyrs

Read Next

All
Israeli Prime Minister Benjamin Netanyahu speaks during a press conference at the Prime minister's office in al-Quds, Occupied Palestine, Sunday, Aug. 10, 2025 (AP)
Politics

Netanyahu deliberately derailing truce with Gaza occupation: Hamas

Irish President Michael Higgins arrives to deliver his speech during a 42nd World Food Day celebration at FAO headquarters in Rome, on Oct. 16, 2023. (AP Photo/Alessandra Tarantino)
Politics

Irish president renews call for UN military intervention in Gaza

US Ambassador to Turkey and Special Envoy to Syria Tom Barrack speaks during an interview with The Associated Press at the US Embassy in Aukar, northern suburb of Beirut, Lebanon, Monday, July 21, 2025 (AP)
Politics

US envoy, Netanyahu discuss restraining attacks on Lebanon, withdrawal

Smoke billows following Israeli airstrikes in multiple areas in Sanaa, Yemen, Sunday, Aug. 24, 2025 (AP)
Politics

Ansar Allah vow sustained Gaza support despite Israeli strikes

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS